Introduction: A cancer diagnosis should not depend on a psychiatric history
Lung cancer is one of the world’s deadliest cancers, but over the past two decades, treatment has become more effective and more personalized. Surgery, chemotherapy, radiotherapy, targeted drugs, and immunotherapy have helped many patients live longer. In theory, these advances should benefit everyone who develops lung cancer. In practice, they do not.
A major new nationwide study from Japan shines a harsh light on a persistent blind spot in cancer care: patients with schizophrenia spectrum disorders, or SSD, were significantly less likely to receive several standard treatments for non-small cell lung cancer (NSCLC), the most common form of lung cancer. The study is important not only because of its size, but because it quantifies something clinicians, patients, and families have long suspected: severe mental illness can shape who gets timely, stage-appropriate cancer treatment.
